Dyne CFO awarded RSUs and 105K stock options

Dyne Therapeutics’ Chief Financial Officer Erick Lucera received new equity awards.

Rhea-AI Filing Summary

Dyne Therapeutics’ Chief Financial Officer Erick Lucera received new equity awards. On February 12, 2026, Lucera was granted 65,000 restricted stock units, each representing one share of common stock, at a grant price of $0. These RSUs are scheduled to vest in equal quarterly installments over four years starting May 12, 2026.

On the same date, Lucera also received a stock option covering 105,000 shares of common stock with an exercise price of $16 per share. This option vests in equal monthly installments over four years through February 12, 2030. Following the RSU grant, Lucera directly beneficially owns 131,100 unvested RSUs.

Insider Trade Summary

Grant/Award: 170,000 shares

Grant/Award 2 txns

Insider Lucera Erick

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	105,000	$0.00	$0.00
Grant/Award	Common Stock	65,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 105,000 contracts (Direct); Common Stock — 131,100 shares (Direct)

Footnotes (3)

1. F1. Consists of shares of Common Stock issuable under 65,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on May 12, 2026.
2. F2. Includes 131,100 unvested RSUs.
3. F3. This option was granted on February 12, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through February 12, 2030.

FAQ

What did Dyne Therapeutics (DYN) disclose about Erick Lucera’s new RSU grant?

Dyne Therapeutics disclosed that CFO Erick Lucera received 65,000 restricted stock units on February 12, 2026. Each RSU converts into one share upon vesting, with the award vesting quarterly over four years starting May 12, 2026, at a grant price of $0.

How many stock options were granted to Dyne Therapeutics (DYN) CFO Erick Lucera?

Erick Lucera was granted a stock option for 105,000 shares of Dyne Therapeutics common stock. The option has a $16 exercise price and vests in equal monthly installments over four years, ending February 12, 2030, reflecting a typical multi‑year executive compensation structure.

What is Erick Lucera’s equity ownership position in Dyne Therapeutics (DYN) after this Form 4?

After the reported RSU grant, Erick Lucera beneficially owns 131,100 unvested restricted stock units in Dyne Therapeutics. These RSUs represent rights to receive common shares as they vest over time, aligning his compensation with the company’s long‑term performance trajectory.

When do Erick Lucera’s newly granted RSUs in Dyne Therapeutics (DYN) start vesting?

The 65,000 RSUs granted to Erick Lucera begin vesting on May 12, 2026. They vest in equal quarterly installments over four years, tying continued service and long‑term company performance to the actual receipt of Dyne Therapeutics common shares.

Over what period will Erick Lucera’s Dyne Therapeutics (DYN) stock options vest?

The 105,000-share stock option granted to Erick Lucera vests over four years. Vesting occurs in equal monthly installments through February 12, 2030, meaning ownership of the underlying shares is earned gradually rather than immediately upon the grant date.

Did Erick Lucera pay anything for the Dyne Therapeutics (DYN) RSUs and options disclosed?

The RSU grant to Erick Lucera was made at a price of $0, reflecting a compensation award rather than a purchase. The stock option has a $16 per-share exercise price, which would be payable only if and when he chooses to exercise vested option shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 05:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lucera Erick

(Last) (First) (Middle)

C/O DYNE THERAPEUTICS, INC.

1560 TRAPELO ROAD

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		A		65,000(1)	A	$0	131,100(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16	02/12/2026		A		105,000		(3)	02/11/2036	Common Stock	105,000	$0	105,000	D

Explanation of Responses:

1. Consists of shares of Common Stock issuable under 65,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on May 12, 2026.

2. Includes 131,100 unvested RSUs.

3. This option was granted on February 12, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through February 12, 2030.

	/s/ Ron Caponigro, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.